+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gocovri

  • ID: 4775088
  • Report
  • June 2018
  • Region: Global
  • 15 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Gocovri (Adamas Pharmaceuticals) is an extended-release formulation of amantadine, uniquely indicated for the treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease. While amantadine has been available as an anti-Parkinson drug since 1968, the specific formulation in Gocovri was approved in August 2017 following investigations into the effect of N-methyl-D-aspartate receptor antagon.on dyskinesia. Gocovri is administered once daily at bedtime, allowing for amantadine levels to slowly increase during the night and peak in the early morning, when dyskinesia episodes are most frequent.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Gocovri : Parkinson's disease

LIST OF FIGURES
Figure 1: Gocovri for Parkinson’s disease – SWOT analysis
Figure 2: The authors drug assessment summary of Gocovri for Parkinson’s disease
Figure 3: The authors drug assessment summary of Gocovri for Parkinson’s disease
Figure 4: Gocovri sales for Parkinson’s disease in the US, 2016–25

LIST OF TABLES
Table 1: Gocovri drug profile
Table 2: Gocovri pivotal trial data in Parkinson’s disease
Table 3: Gocovri sales for Parkinson’s disease in the US ($m), 2016–25
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll